Fragment-Based Discovery of the Pyrazol-4-yl Urea (AT9283), a Multitargeted Kinase Inhibitor with Potent Aurora Kinase Activity

Citations Over TimeTop 1% of 2008 papers

Abstract

Here, we describe the identification of a clinical candidate via structure-based optimization of a ligand efficient pyrazole-benzimidazole fragment. Aurora kinases play a key role in the regulation of mitosis and in recent years have become attractive targets for the treatment of cancer. X-ray crystallographic structures were generated using a novel soakable form of Aurora A and were used to drive the optimization toward potent (IC(50) approximately 3 nM) dual Aurora A/Aurora B inhibitors. These compounds inhibited growth and survival of HCT116 cells and produced the polyploid cellular phenotype typically associated with Aurora B kinase inhibition. Optimization of cellular activity and physicochemical properties ultimately led to the identification of compound 16 (AT9283). In addition to Aurora A and Aurora B, compound 16 was also found to inhibit a number of other kinases including JAK2 and Abl (T315I). This compound demonstrated in vivo efficacy in mouse xenograft models and is currently under evaluation in phase I clinical trials.

Related Papers

• → Aurora Kinase Inhibitors: Current Status and Outlook(2015)281 cited
• → VX-680 Inhibits Aurora A and Aurora B Kinase Activity in Human Cells(2007)118 cited
• → Mitotic requirement for aurora A kinase is bypassed in the absence of aurora B kinase(2005)114 cited
• → CDKN1A-mediated responsiveness ofMLL-AF4-positive acute lymphoblastic leukemia to Aurora kinase-A inhibitors(2013)9 cited
• MLN8054, an orally active Aurora A kinase small molecule inhibitor in phase I clinical trials(2006)